• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enfusion Inc Cl A (NY: ENFN )

    8.560 -0.090 (-1.04%)
    Official Closing Price Updated: 4:10 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 133,867
    Open 8.620
    Bid (Size) 6.500 (1)
    Ask (Size) 8.750 (2)
    Prev. Close 8.650
    Today's Range 8.510 - 8.660
    52wk Range 7.520 - 11.56
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Enfusion To Present at Upcoming Investor Events
    From Enfusion, Inc.
    Via Business Wire
    ENFN Stock Earnings: Enfusion Beats EPS, Beats Revenue for Q1 2024
    ENFN stock results show that Enfusion beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -8.64%
    -8.64%
    1 Month
    -1.72%
    -1.72%
    3 Month
    -10.83%
    -10.83%
    6 Month
    -7.96%
    -7.96%
    1 Year
    -23.43%
    -23.43%

    More News

    Read More
    Enfusion Announces First Quarter 2024 Results
    From Enfusion, Inc.
    Via Business Wire
    Enfusion Announces Date of First Quarter 2024 Results
    From Enfusion, Inc.
    Via Business Wire
    A Glimpse Into The Expert Outlook On Enfusion Through 4 Analysts
    Via Benzinga
    Earnings Outlook For Enfusion
    Via Benzinga
    JP Morgan Downgrades Enfusion: Here's What You Need To Know
    Via Benzinga
    The 3 Most Undervalued Under-$10 Stocks to Buy in April 2024
    Via InvestorPlace
    Kayne Anderson Strengthens Investment Operations After Successful Platform Migration to Enfusion
    From Enfusion
    Via Business Wire
    Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
    Via InvestorPlace
    12 Information Technology Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Enfusion Announces Fourth Quarter 2023 Results and Full Year 2023 Results
    From Enfusion, Inc.
    Via Business Wire
    Earnings Scheduled For March 12, 2024
    Via Benzinga
    Wall Street's Top 10 Stock Calls This Week - Saturday, March 2
    Via Talk Markets
    Enfusion Stock To Remain Range-Bound In 2024 Amid Stable Hedge Fund Market: Goldman Sachs Analyst Downgrades Stock
    Via Benzinga
    Enfusion Announces Date of Fourth Quarter and Full Year 2023 Results
    From Enfusion, Inc.
    Via Business Wire
    Enfusion to Host Investor Day on March 19, 2024
    From Enfusion, Inc.
    Via Business Wire
    This Analyst With 84% Accuracy Rate Sees Around 13% Upside In Darden Restaurants - Here Are 5 Stock Picks For 2023 From Wall Street's Most Accurate Analysts
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Hidden Gems: 3 Small-Cap Tech Stocks With Huge Potential
    Via InvestorPlace
    Enfusion Announces Appointment of Chief Operating Officer
    From Enfusion, Inc.
    Via Business Wire
    Enfusion Announces Third Quarter 2023 Results
    From Enfusion, Inc.
    Via Business Wire
    Enfusion Announces Date of Third Quarter 2023 Results
    From Enfusion, Inc.
    Via Business Wire
    Enfusion Launches Portfolio Workbench, Empowering Portfolio Managers to Seamlessly Rebalance Multi-Asset Portfolios
    From Enfusion, Inc.
    Via Business Wire
    The 3 Most Undervalued Under-$10 Stocks to Buy in September 2023
    Via InvestorPlace
    Enfusion Announces Closing of New $100 Million Credit Facility
    From Enfusion, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.